

REMARKS/ARGUMENTS

The communication mailed October 28th comprised a restriction requirement. The Examiner wishes to divide the claims in Group I, claims 1 through 11, drawn to compounds, and Group II, Claims 12 through 15, drawn to various methods of treating pathological conditions.


Applicants, through their attorney, hereby elect for further prosecution the invention designated as Group I. Claims 1 through 15 as originally filed, are accordingly withdrawn. As requested by the Examiner, applicants are adding claims directed to a smaller set of compounds. In particular, applicants have restricted in newly added claim 16 the meaning of both R₃ and R₄. Additionally, a new claim 17 has been added which has a smaller Markush group than that of claim 5 as filed. Finally, applicants elect as single species, compound (b) of claim 5 as filed. Claim 18 is directed at this species.

Application No. 10/625,101
Amdt dated December 2, 2005
Reply to Office action of October 28, 2005

Since applicants did not claim an intermediate compound (see specification at page 56, line 13), a claim to such compound (1-acetyl-6-fluoro-2-indoline) has been added at this time.

All elections are without traverse.

Respectfully submitted,




Mary-Ellen M. Devlin
Attorney for Applicant(s)
Reg. No. 27,928

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4866
Dated: December 2, 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on December 2, 2005



By: Mary-Ellen M. Devlin
Reg. No. 27,928